Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

ies Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(r) and Neurontin(r), the effects of competition on our innovative products, especially Copaxone(r) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not cove
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:11/26/2014)... 25, 2014  goBalto, Inc., the leading provider of ... a winner of Red Herring,s Top 100 Global ... North America award in 2013, marking its emergence as ... Red Herring,s Top 100 Global list has become ... and entrepreneurs. Red Herring editors were among the first ...
(Date:11/26/2014)...   Heska Corporation (NASDAQ: HSKA ) ... of advanced veterinary diagnostic and other specialty veterinary products ... will attend The Benchmark Company, LLC,s Micro Cap Discovery Conference ... held at The Palmer House Hilton, 17 E. Monroe Street, ... 2:30 p.m. Please email hska@haydenir.com or contact your ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/28/2014)... November 28, 2014 Dr. Paul Vitenas, one of ... a Glitter & Glow Holiday Event for those in the area ... at his practice. Glitter & Glow will take place on December ... new location in the heart of Houston at 4208 Richmond Ave. ... and hope that you will come and celebrate the season with ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PreDiabetes Centers , a ... employees learn their risk for type 2 diabetes ... a local school in partnership with the American ... , As the Presenting Sponsor for the ... is co-hosting diabetes-prevention presentations at Austin-area companies with ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 More ... have now been filed in a New Jersey ... implants, Bernstein Liebhard LLP reports. , A ... County Superior Court reflects the filing of 2,160 ... hip stems, which were voluntarily recalled on July ...
(Date:11/28/2014)... 28, 2014 Patten Pecans, based in ... With those passions driving them, they've added a pecan ... tried other pecans oils, they've found this pecan ... be exceptionally flavorful, retaining the buttery pecan notes that ... nutritional benefits found in pecans nuts is found ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... older we get, the ,more difficulty we seem to have remembering ... each morning, but unless we park in the ,same space each ... whether we left the SUV in the second or fifth row. ... and will have forgotten ,their names before the handshake is over. ...
... - 13 May 2011 Elsevier, the world,s ... announced today that Syngene, India,s first contract research ... provide unlimited access to Reaxys for all Syngene ... competitiveness and productivity in the ever-expanding and highly ...
... , FRIDAY, May 13 (HealthDay News) -- A common ... the development of life-threatening heart arrhythmias (when the heart ... a new study. In pinpointing this gene, ... help doctors determine which patients are likely to benefit ...
... Lombard, IL, May 13, 2011 Dynamic chest ... compression has been well studied in events such ... not been studied during chiropractic manipulation. In a ... of Manipulative and Physiological Therapeutics , researchers quantified ...
... Ga. In a time of transition for rural ... them stay focused on their goals and avoid potential ... an ongoing University of Georgia study., The study, published ... of Community Psychology, is part of a broader ...
... New data offer hints to why Parkinson,s disease so ... say researchers at Washington University School of Medicine in ... communications including the signals that control movement. As Parkinson,s ... problems moving and other symptoms. The new research ...
Cached Medicine News:Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Gene Variant Linked to Sudden Cardiac Death Risk in Blacks 2Health News:Chiropractic manipulation results in little or no risk of chest injury 2Health News:Study finds youth-mentor relationships particularly helpful for those experiencing hardship 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 3
5 inch (12.7 cm), 2 x 5 mm blade....
Nicati foreign body spud....
In reversible handle for removing foreign bodies....
... Focus Night & Day soft contact ... to protect the cornea and to relieve ... or chronic ocular pathologies such as bullous ... corneal dystrophies as well as post-surgical conditions ...
Medicine Products: